Details

Autor(en) / Beteiligte

• Kilickap, Saadettin
• Ak, Sertac
• Dursun, Oldac U
• Sendur, Mehmet An
• Karadurmus, Nuri
• Demirci, Umut

Titel

Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events

Ist Teil von

• Future oncology (London, England), 2023-09, Vol.19 (29), p.2003-2012

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2023

Beschreibungen/Notizen

• The use of tyrosine kinase inhibitors has made a breakthrough in the treatment of non-small-cell lung cancer (NSCLC). Recently, lorlatinib, a third-generation tyrosine kinase inhibitor, has demonstrated significant systemic and intracranial activity in both first-line and subsequent-line therapy in ALK-positive NSCLC patients. In this review, general characteristics of lorlatinib, its efficacy in the treatment of ALK-positive NSCLC patients and the safety of lorlatinib, particularly addressing CNS adverse events, are discussed. Management of CNS adverse events, which seem to be specific to lorlatinib therapy, is outlined. Lung cancer is a common disease and affects patients badly. Lorlatinib is a new and useful drug for this disease. But this drug has also some undesirable effects for the brain. These effects are generally mild and can be treated. This article discusses the undesirable effects of this drug on the brain and how to cope with these effects.